Dynavax Technologies (NASDAQ:DVAX) Given New $10.00 Price Target at The Goldman Sachs Group

Dynavax Technologies (NASDAQ:DVAX) had its target price reduced by equities research analysts at The Goldman Sachs Group from $12.00 to $10.00 in a report issued on Thursday,Benzinga reports. The firm presently has a “sell” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price target would indicate a potential downside of 2.88% from the stock’s previous close.

A number of other equities research analysts have also commented on DVAX. William Blair reiterated an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Monday, February 24th. Finally, HC Wainwright reissued a “buy” rating and issued a $31.00 price objective on shares of Dynavax Technologies in a report on Friday, February 21st.

Dynavax Technologies Stock Down 3.3 %

Dynavax Technologies stock opened at $10.30 on Thursday. Dynavax Technologies has a twelve month low of $9.74 and a twelve month high of $14.63. The business has a fifty day moving average of $12.98 and a two-hundred day moving average of $12.56. The firm has a market cap of $1.28 billion, a P/E ratio of 57.21 and a beta of 1.26. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.05. The business had revenue of $72.03 million for the quarter, compared to analyst estimates of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. On average, analysts forecast that Dynavax Technologies will post 0.32 earnings per share for the current fiscal year.

Institutional Trading of Dynavax Technologies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. grew its holdings in Dynavax Technologies by 96.5% in the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 1,169 shares during the period. Smartleaf Asset Management LLC increased its stake in shares of Dynavax Technologies by 463.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 2,034 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Dynavax Technologies during the 4th quarter worth about $35,000. GAMMA Investing LLC lifted its stake in Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 1,457 shares in the last quarter. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in Dynavax Technologies in the 4th quarter worth about $71,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.